This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
If a patient assigned to the rotational strategy first experienced failure with methotrexate they were changed to a therapy of cyclosporine in rotation with the escape therapy for the remainder of the therapy or until cyclosporine failed, in which case the patient received the escape therapy for the remainder of the study.
Patients assigned to the rotational strategy alternated annually between receiving modified cyclosporine (Neoral) at a dose of 250 mg/day (3.0 -3.5 mg/kg per day for patients weighing 71 -84 kg) and methotrexate (dose as above). Patients continued on this rotation unless they experienced failure with one of the treatments. If patients experience treatment failure whilst receiving cyclosporine they were assigned to continuous therapy with methotrexate for the remainder of the study, or until failure with methotrexate occurred. In the case of failure with methotrexate, the patients were assigned to continuous treatment with the escape therapy until the end of the study.
The escape therapy was not a specific treatment. It represented alternative treatments that were assumed to provide no additional benefits, but to merely provide maintenance treatment for psoriasis.
Type of intervention
Treatment.
Economic study type
Cost-effectiveness analysis.
Study population
The study population comprised patients with moderate to severe psoriasis. Inclusion and exclusion criteria were not reported.
Setting
The setting was not explicitly reported, but it would appear to have been primary care. The economic study was carried out in the USA.
Dates to which data relate
The years when the effectiveness and resource use data were collected were not reported. The price year for all costs was unclear. However, the authors stated that the cost of escape therapy was estimated from 1999 prices.
Source of effectiveness data
The effectiveness data were derived from a synthesis of published results. Where evidence was inconclusive or unavailable, expert opinion was sought.
Modelling
The course of the disease and the incidence of adverse events under different treatment strategies were modelled using decision trees with embedded Markov processes.
Outcomes assessed in the review
The outcomes assessed were changes in clinical status relating to the treatment strategies that were modelled.
Study designs and other criteria for inclusion in the review
The authors looked for evidence from randomised controlled trials. Other inclusion and exclusion criteria were not reported.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The following effectiveness results were derived both from published material and from expert opinion. The results were presented according to clinical status (severe, moderate, mild, clear) at the end of that year.
The percentages of patients with severe psoriasis who had received methotrexate for one year were severe 8%, moderate 45%, mild 45%, and clear 2%. measures were used selectively or whether the derived measures were combined. A lack of reported detail makes it impossible to comment on the impact of differences between the primary studies when estimating effectiveness. The methods used to derive measures of effectiveness from expert opinion were not reported. Estimates of the relative effectiveness of methotrexate and cyclosporine in producing improvement and clearance were investigated in a sensitivity analysis. The ranges used appear to have been wide.
Validity of estimate of measure of benefit
The estimation of benefits was obtained directly from the effectiveness analysis. This estimate was chosen as the primary outcome measure because studies had shown that patients highly value the clearing of psoriasis lesions.
Validity of estimate of costs
The authors only reported a partial list of cost inputs, so it is not possible to comment on whether all the categories of cost and the costs relevant to each category have been included in the study, or whether any omissions are likely to have affected the authors' conclusions. The costs and the quantities were not reported separately. Some quantities appear to have been taken from published sources, whereas the sources of other quantities were unclear. A sensitivity analysis of the quantities was not conducted. It is possible that this may limit the interpretation of the study findings. Prices were taken from published sources. A sensitivity analysis of the prices was not conducted. Discounting was not undertaken even though the costs were incurred during a 10-year period. It does not appear that charges were used to proxy costs. The date to which the prices related was unclear.
